✦ LIBER ✦

Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data

✍ Scribed by G. Grana

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 112 KB
Volume: 93
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.20564

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone‐sensitive early breast cancer. However, the side‐effects associated with tamoxifen therapy have prompted a search for safer and potentially more effective endocrine agents. Results from randomized trials of the third‐generation aromatase inhibitors, anastrozole, letrozole and exemestane, demonstrating improved efficacy compared with tamoxifen and favorable tolerability profiles, are discussed in this review. J. Surg. Oncol. 2006;93:585–592. © 2006 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

The impact of tumor progesterone recepto

The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer : A decision analysis

✍ Rinaa S. Punglia; Karen M. Kuntz; Eric P. Winer; Jane C. Weeks; Harold J. Burste 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 354 KB 👁 1 views